Immune tolerance
IM injection breaks immune tolerance to activate B cells & produce polyclonal antibodies
InPeutics · Immunotherapy
Harnessing the body's intelligence to create accessible multi-targeted immunotherapies
BROAD POTENTIAL
Clinically validated approach with broad application across diseases - including oncology and autoimmune disorders
RAPID DEVELOPMENT
Proprietary technology allows for rapid development of novel therapies with multiple advantages over mAbs
ACCESS
Modality & RoA reduces cost & treatment burden, supporting patient access and quality of life.
Technology
Our proprietary technology platform enables the design of novel fusion molecules that combine our patented synthetic carrier construct with multiple antigens targeting specific proteins of interest. This approach breaks immune tolerance, stimulating the production of polyclonal antibodies that transiently deplete overexpressed ligands and cytokines, restoring them to normal physiological levels.
How the technology works
Targeting
Polyclonal antibodies target multiple circulating ligands or cytokines
Tumor response
Tumor and environment are inactivated through depletion of ligands as fuel source
Pipeline
A focused oncology portfolio built from one repeatable immunotherapy platform.
Development portfolio
From discovery to the clinic
IN01 is the lead clinical-stage asset, supported by four programs in discovery.
IN01Lead programEGFSingle targetColorectal cancer · NSCLCPhase Ib
Colorectal cancer
BRAF V600E and wild-type · Trials 1 and 2
Phase Ib approved 2021CTA reactivation in progressNSCLC
Rare EGFR mutations · EPICAL II: IN01 + osimertinib
Phase Ib plannedIN02VEGF-A / VEGF-DBi-specificAngiogenesis · multiple solid tumoursDiscovery
IN03EGF / TGFαBi-specificLung · colorectal · head & neck · mesotheliomaDiscovery
IN04EGF / NRG1Bi-specificBreast cancerDiscovery
IN05FGF2Single targetColorectal cancerDiscovery
Development model
A repeatable route to new programs
The approach behind IN01 can be applied to further growth factors.
Select
Identify a growth factor behind tumour growth or treatment escape.
IN01 targets EGFDesign
Use the CTB carrier to raise neutralising antibodies.
IN01 fusion proteinCombine
Pair with an inhibitor to remove the ligand it cannot reach.
IN01 plus an EGFR-TKIExpand
Apply the route to another pathway or multiple targets.
IN11 and beyond
Platform advantages
Built to extend beyond one molecule
A shared carrier provides precedent while every new target retains program-specific validation.
A reusable GMP platform
A shared process architecture can accelerate development, while each construct receives product-specific CMC validation.
The patient makes the antibodies
An endogenous polyclonal response from IM injections — no monoclonal bioprocessing and no infusions.
Ligand-level targeting
Depleting EGF spares tissues that rely on other ligands, avoiding the skin and GI toxicity of receptor blockade.
A strong combination partner
Low treatment burden and no competition with the backbone; IN01 enhanced every inhibitor class tested.
Mono- or bi-specific from one carrier
One or two targets in a single injection, with five programs developed from the same platform.
Each program starts with precedent
IN01 provides platform precedent; each new target completes its own GLP tox, CMC validation and regulatory filing.
Team
Johan Indot
Co-Founder & CEO InPeutics
Erik D’Hont
Co-Founder & CSO InPeutics
Michael Meister, Ph.D.
CMC & Tech Ops
Sylvia Gan
Clinical Trials
John Serio
Advisor – IP
Keith Charlton, PhD
Advisor – Molecule Design
Dr. Rafael Rosell
Advisor – NSCLC